CA-CEPTON-TECHNOLOGIES
9.9.2019 15:02:04 CEST | Business Wire | Press release
CNL Software, a world leader in Physical Security Information Management (PSIM) software, is pleased to announce a technology partnership with Cepton Technologies, a developer of industry-leading 3D sensing solutions, at the GSX in Chicago. The partnership will drive the automation of threat detection, tracking and escalation in real time using the latest PSIM, LiDAR and video assessment technologies.
Cepton Technologies’ Helius™ system is a smart lidar network utilizing edge computing to provide real-time detection, tracking and classification. It can seamlessly track an object from sensor to sensor, providing 3D data on location, dimensions, and velocity, while maintaining the same identification of the object.
By connecting multiple laser-powered sensors, it offers comprehensive coverage of a given area as well as high resolution imaging of objects. Sensors can be clustered as needed but act as one to maximize the simplicity of use and integration. With the in-built software in the hardware unit, Helius is browser-based and can launch on computers and mobile devices for instant monitoring and configuration, without installations of additional software. Furthermore, being edge-based, Helius processes data locally and outputs low-bandwidth data to the central server.
“CNL Software is committed to working with new and innovative technologies that will give our customers improved security and greater efficiency. Cepton’s lidar sensor technology brings the technological leaps that have taken place in autonomous vehicles to the security industry, especially in the government and critical infrastructure markets where we are experiencing growing demand for the integration of multiple different security system and sensor technologies,” comments Keith Bloodworth, CEO, CNL Software. “When integrated with IPSecurityCenterTM , Helius further enhances the industry’s most comprehensive PSIM system solution, providing users with access to more of the tools they need to quickly see, understand, assess and properly resolve perimeter security and surveillance incidents, consistently.”
Neil Huntingdon, Cepton’s VP of Business Development, added: “Our technology’s ability to detect and track events in traditionally difficult environments combined with IPSecurityCenter’s ability to correlate this data with data from other security systems and sensors and provide decision support is a powerful proposition. We’re really excited to be partnering with CNL Software to bring this game changing solution to the government, critical infrastructure, safe city and transportation markets, in particular. It will unlock that ‘missing layer’ by filling the medium-range sensor gap and improve it with the capability to classify objects as well as behaviors.”
For more information about CNL Software’s PSIM solution and deployments, please visit Booth #1713 at the GSX in Chicago on September 10– 12 2019. To book a demonstration, please email marketing@cnlsoftware.com
About Cepton Technologies, Inc.
Cepton Technologies, Inc. is a 3D sensing solutions provider shipping state-of-the-art lidar products for the automotive, security, transport infrastructure, industrial, IoT and mapping markets.
Founded in 2016 and led by industry veterans with deep experience in lidar and advanced imaging, Cepton is focused on the mass market commercialization of high performance, high quality lidar solutions for the automotive industry and beyond.
Cepton’s patented lidar technology delivers outstanding detection range and resolution, reliability and affordability, to enable perception for the fast-growing market for autonomous and smart machines. For more information, visit: http://www.cepton.com/ .
Cepton will also have a separate booth at stand 1894, next to the bistro.
About CNL Software
More than a decade ago, we set out to create a PSIM platform to transform the way organizations manage their physical security. Today, IPSecurityCenter is trusted by the best-informed security operations in national security, critical infrastructure and large enterprises around the world. For more information, visit www.cnlsoftware.com .
Physical Security Information Management (PSIM) LinkedIn Group
The PSIM Group brings together users, integrators, consultants and manufacturers of Physical Security Information Management software to share ideas, thought leadership, tips, tricks, future developments and more! Please follow visit https://www.linkedin.com/groups/2162880
View source version on businesswire.com: https://www.businesswire.com/news/home/20190909005033/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom